PBM Legislation and the PBM-affiliated GPOs | AMCP 2024
Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, discusses whether proposed transparency rules in the pharmacy benefit manager (PBM) legislation that Congress is considering might apply to the PBM-affiliated group purchasing organizations.
The pharmacy benefit manager (PBM) bills that Congress is currently considering include a variety of new transparency and reporting rules. Whether those rules would apply to the group purchasing organizations (GPOs) affiliated with the major PBMs is an open question
Ross Margulies, J.D., M.P.H., a partner at Foley Hoag, a law firm headquartered in Boston, discussed PBMs and the PBM legislation today at the 2024 annual meeting of the Academy of Managed Care Pharmacy (AMCP).
In an interview with Managed Healthcare Executive prior to the meeting, Margulies said that most of the bills under consideration have provisions aimed at "affiliated entities" that might include the group purchasing organizations (GPOs).
Margulies also noted that the term PBM is not currently defined in most statutes and that the some of the definitional language in the current bills “could reach affiliated, PBM-owned GPOs.”
Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024
April 18th 2024After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
Read More
Potential Generics Could Lower Prices for Oncology, Cardiovascular Drugs | AMCP 2024
April 18th 2024Up to 50 generics could be approved this year, including Victoza to treat patients with diabetes. If generics of Victoza become available, this would the first GLP-1 to face generic competition.
Read More
Are Value-Based Contracts the Answer to Ultra-High-Priced Gene Therapies? | AMCP 2024
April 17th 2024Innovative contracts are becoming more common for gene therapies. They aim to balance a therapy’s cost-effectiveness and affordability, as well as address the uncertainty of long-term benefit.
Read More
